Cardiovasculaire Geneeskunde.nl

Protecting the heart and the kidney: Implications from the SHARP trial

Slides (presentatie) - Nov. 9, 2011

Protecting the heart and the kidney:Implications from the SHARP trial


Prof. Jane Armitage – Professor of Clinical Trials and Epidemiology
Clinical Trials Service Unit & Epidemiological Study Unit
University of Oxford, United Kingdom
 


Bekijk of download de presentatie

klik voor bekijken op onderstaande afbeeldingen




Cardiovascular Exchange Summit 2011

Cardiovascular mortality in haemodialysis patients

Causes of death in dialysis patients

Serum cholesterol and relative risk of death

Proportional effects on MAJOR VASCULAR EVENTS

SHARP: Rationale

SHARP: Eligibility

SHARP: Assessment of LDL-lowering

SHARP: Main outcomes

SHARP: Baseline characteristics

RENAL STATUS

LIPID PROFILE at initial randomization

SHARP: Compliance and LDL-C reduction at study midpoint

SHARP: Compliance and LDL-C reduction at study midpoint

SHARP: Major Atherosclerotic Events

CTT: Effects on Major Atherosclerotic Events

CTT: Effects on Major Atherosclerotic Events

CTT: Effects on Major Atherosclerotic Events

SHARP: Major Atherosclerotic Events

SHARP: Cause-specific mortality

SHARP: Renal outcomes

SHARP: estimated rate of change in eGFR

SHARP: Cancer incidence

SHARP: Safety

SHARP: Conclusions

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: